ライフサイエンスコーパス: large clinical trial

1 iple myeloma treated within the context of a large clinical trial.

2 MM showing significant clinical benefit in a large clinical trial.

3 o reduce heart failure mortality in a recent large clinical trial.

4 reast cancer masses found on mammograms in a large clinical trial.

5 oducible method is needed for application to large clinical trials.

6 d potentially reduce the frequency of failed large clinical trials.

7 he performance of haemorrhage descriptors in large clinical trials.

8 ll-cause mortality compared with warfarin in large clinical trials.

9 diabetic macular edema has been proven with large clinical trials.

10 , but such a strategy has not been tested in large clinical trials.

11 ons that are currently being investigated in large clinical trials.

12 ent CETP inhibitors, are now being tested in large clinical trials.

13 efficacy against severe rotavirus disease in large clinical trials.

14 predicts antidepressant outcomes within two large clinical trials.

15 adhesion and increased patient mortality in large clinical trials.

16 ssociated with outcome within the context of large clinical trials.

17 fects, are being tested (or soon will be) in large clinical trials.

18 e of these mutations has not been defined in large clinical trials.

19 ed in patients treated with ezetimibe in two large clinical trials.

20 ng polyps varies widely in recently reported large clinical trials.

21 hniques are currently under investigation in large clinical trials.

22 one intravitreal implant (DEX) has varied in large clinical trials.

23 late ARDS support the need for confirmatory large clinical trials.

24 t the benefit of multiple recently published large clinical trials.

25 ent of the CHD risk associated with sdLDL in large clinical trials and has demonstrated convincingly

26 al Health and Nutrition Examination Surveys, large clinical trials and meta-analyses for statin benef

27 Large clinical trials and observational studies should c

28 ntagonists, have been investigated in recent large clinical trials and show significant promise both

29 Finally, 2 large clinical trials are formally putting the inflammat

30 Large clinical trials are now planned to confirm or refu

31 rate the research process, particularly when large clinical trials are required.

32 ride-lowering therapies remains uncertain, 2 large clinical trials are testing the influence of omega

33 Large clinical trials are the criterion standard for mak

34 In a large clinical trial cohort of patients with IPF (n = 1,

35 tter (AFL) compared with chlorthalidone in a large clinical trial cohort with extended post-trial sur

36 Results from recent large clinical trials confirm that blunting of the renin

37 However, additional large clinical trial data are required to more definitiv

38 ioverter-defibrillators (ICDs) after several large clinical trials demonstrated their ability to effe

39 When the results of two large clinical trials, ESPRIT and SILCAAT, showed no cli

40 A large clinical trial evaluating the impact of IL-1beta i

41 lly to reduce new cases of colon cancer in 2 large clinical trials evaluating coronary events, althou

42 In fact, all three large clinical trials failed to confirm estrogen's expec

43 No large clinical trials have addressed the role of antioxi

44 Although large clinical trials have been formed to use this thera

45 , and patient satisfaction, data from recent large clinical trials have called the safety of this tec

46 Large clinical trials have clearly demonstrated morbidit

47 Two large clinical trials have demonstrated that fixed-dose

48 effects on thrombotic processes in vivo, but large clinical trials have failed to show benefits of 5-

49 The results of recent large clinical trials have modified treatment plans form

50 Secondary outcomes in these large clinical trials have shown that VEGF inhibition im

51 Recent large clinical trials have supported the use of radiatio

52 ere measured before and after treatment in a large clinical trial in AAV: 163 subjects enrolled in th

53 A large clinical trial in coronary heart disease patients

54 Data from a large clinical trial in predominantly white US women (19

55 f individual patients, as well as to analyze large clinical trials in CML.

56 Despite several large clinical trials in lupus nephritis, no second line

57 We summarize the results of the available large clinical trials in our understanding of the manage

58 etrapib and torcetrapib, have been tested in large clinical trials in statin-treated coronary heart d

59 d in the conduct and reporting of results of large clinical trials in these functional disorders are

60 ring LABA therapy and should be evaluated in large clinical trials including the current FDA-mandated

61 everal LMWH agents that have been studied in large clinical trials, including enoxaparin, dalteparin,

62 Recently published large clinical trials, including the long-term results f

63 Although two large clinical trials investigating the fat/breast cance

64 In two large clinical trials, investigators found a potential r

65 The experience from 2 large clinical trials involving the oral intake of 2000

66 A long-term large clinical trial is necessary to investigate the ben

67 A long-term large clinical trial is necessary to investigate the saf

68 iers outlined herein before the next wave of large clinical trials is under way.

69 diatric asthma clusters by using a separate, large clinical trials network.

70 sis was conducted among participants in this large clinical trial of calcium supplementation to preve

71 A large clinical trial of these naturally occurring substa

72 Based on a secondary analysis of data from a large clinical trial of trimethoprim-sulfamethoxazole pr

73 As demonstrated in large clinical trials of 2 to 4 years' duration, these m

74 rocess and outcomes are compared between two large clinical trials of LDL cholesterol reduction with

75 Data from 2 large clinical trials of peginterferon and ribavirin wer

76 Few long-term, large clinical trials of soy as a means of improving bon

77 ty from breast cancer chemotherapy, and even large clinical trials often do not report this informati

78 Two large clinical trials, one open-label (Stroke Prevention

79 ording to prospectively recorded data from a large clinical trial, patients whose colon cancer was re

80 ble, recent review articles and results from large clinical trials, preferably with outcomes from man

81 Several large clinical trials provide additional evidence indica

82 Three large clinical trials provoked major debate when hormone

83 en (Arg506Gln; FV Leiden), was examined in a large clinical trial (PROWESS) of severe sepsis and a mo

84 therapy (HRT) effects, and the first of the large clinical trials published its results during the p

85 e Hypertension Prevention Trial, three other large clinical trials reported differing effects of sodi

86 Recent large clinical trials show lower rates of late cardiovas

87 A large clinical trial showed short and long-term efficacy

88 Two large clinical trials showed marked reduction in acute c

89 be critical to include elderly asthmatics in large clinical trials so that therapy may be better tail

90 y responsiveness) of asthmatic children in a large clinical trial spanning 4 years.

91 Although 2 large clinical trials suggest a neutral effect on cardio

92 ted in clinical trials, subgroup analysis of large clinical trials suggests they may be less likely t

93 The aggregate of large clinical trials supports the notion that statins m

94 redictors of remission and side effects in a large clinical trial that also incorporated cognitive as

95 ent cases and controls were derived from two large clinical trials that compared thalidomide with con

96 Drawing from 5 large clinical trials that included all-trans retinoic a

97 ased on the results of three groundbreaking, large, clinical trials that demonstrated a significantly

98 s been the subject of two recently completed large clinical trials, the Ocular Hypertension Treatment

99 In a large clinical trial, this new drug was found to reduce

100 We examined data from a large clinical trial to determine if chemotherapy dosing

101 We examined follow-up data from a large clinical trial to prospectively investigate the lo

102 ll-cell lung cancer who were randomized in a large clinical trial to receive intensive doxorubicin, c

103 Recent findings include several new large clinical trials, using both gene and protein thera

104 Using baseline data from a large clinical trial, we tested the discriminant validit

105 spite much basic research and many small and large clinical trials, we still do not know how angioten

106 rom mechanistic studies and clinical trials, large clinical trials with SGLT2 inhibitors are now inve